Fears that existing COVID-19 monoclonal antibody therapies could have much diminished efficacy against the new rapidly spreading Omicron variant have been confirmed by initial tests – though, as predicted, one or two have retained some potency.
Four separate studies using pseudovirus assays were published as pre-prints this week, from academic research teams in Germany,